China Doing Very Well in Covid-19 Fight: Qiming Venture Partners

The transcript discusses the efforts of Chinese companies in fighting COVID-19, highlighting advancements in diagnostics, drug development, and vaccines. It covers the challenges faced by CanSino Biologics in clinical trials and the impact of geopolitical tensions on healthcare innovation. The discussion also touches on private equity funding and investment trends in China, noting a decline in VC investments and the shift in company listings from the US to Hong Kong.

How did China's capability in developing diagnostic tests during COVID-19 compare to the SARS outbreak?

• China had no diagnostic tests during COVID-19.

• China had fewer diagnostic tests during COVID-19 than SARS.

• China developed over 100 diagnostic tests within weeks during COVID-19.

• China relied on foreign tests during COVID-19.

What is a significant challenge for CanSino Biologics in conducting phase three clinical trials?

• Regulatory issues in China

• Lack of scientific expertise

• Lack of funding

• Insufficient patient numbers in China

What is a potential impact of US-China geopolitical tensions on Chinese healthcare companies?

• Chinese companies considering listing in Hong Kong

• More Chinese companies listing in the US

• Decreased innovation in China

• Increased collaboration with US companies

What is one of the strategies Chinese healthcare companies are considering due to geopolitical tensions?

• Increasing partnerships with US companies

• Focusing solely on domestic markets

• Listing on the Star board

• Reducing R&D investments

What trend was observed in venture capital investment in China during the first quarter of the COVID-19 pandemic?

• Investment dropped by 40%

• Investment remained stable

• Investment increased by 40%

• Investment was unaffected

What is a reason for the extended time for VC investment returns mentioned in the transcript?

• Increased competition

• Longer time for exits

• Higher initial investments

• Fewer investment opportunities

What was the impact of COVID-19 on the valuations of companies seeking investment?

• Valuations increased significantly

• Valuations were not mentioned

• Valuations remained unchanged

• Valuations decreased